Building the Evidence Base of Blood-Based Biomarkers for Early Detection of Cancer: A Rapid Systematic Mapping Review

EBioMedicine

Volumn 10, Issue , 2016, Pages 164-173

  Uttley, Lesley ^a   Whiteman, Becky L ^b,c   Woods, Helen Buckley ^a   Harnan, Susan ^a   Philips, Sian Taylor ^c   Cree, Ian A ^b,d  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b Faculty of Engineering and Computing   (United Kingdom)

^c UNIVERSITY OF WARWICK   (United Kingdom)

^d UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

Author keywords

Assay; Biomarker; Blood; Cancer; Diagnosis; Early detection; Systematic review

Indexed keywords

BIOLOGICAL MARKER; VOLATILE ORGANIC COMPOUND; TUMOR MARKER;

ARTICLE; BLOOD; BLOOD CLOTTING; CANCER PROGNOSIS; CANCER SCREENING; COLORECTAL CANCER; DATA MINING; EARLY CANCER DIAGNOSIS; HUMAN; LUNG CANCER; PRIORITY JOURNAL; SCREENING TEST; SYSTEMATIC REVIEW (TOPIC); VALIDATION STUDY; BIOLOGY; EVIDENCE BASED MEDICINE; META ANALYSIS; NEOPLASMS; PROCEDURES; WORKFLOW;

BIOMARKERS, TUMOR; COMPUTATIONAL BIOLOGY; DATA MINING; EARLY DETECTION OF CANCER; EVIDENCE-BASED MEDICINE; HUMANS; NEOPLASMS; WORKFLOW;

EID: 84985915610     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2016.07.004     Document Type: Article

References (31)

1. Barak, V., Holdenrieder, S., Nisman, B., Stieber, P., Relevance of circulating biomarkers for the therapy monitoring and follow-up investigations in patients with non-small cell lung cancer. Cancer Biomark. 6:3–4 (2010), 191–196.
2. Beije, N., Jager, A., Sleijfer, S., Circulating tumor cell enumeration by the CellSearch system: the clinician's guide to breast cancer treatment?. Cancer Treat. Rev. 41:2 (2015), 144–150.
3. Berruti, A., Torta, M., Piovesan, A., et al. Biochemical picture of bone metabolism in breast cancer patients with bone metastases. Anticancer Res. 15:6B (1995), 2871–2875.
4. Clancy, C., Joyce, M.R., Kerin, M.J., The use of circulating microRNAs as diagnostic biomarkers in colorectal cancer. Cancer Biomark., 2014.
5. Cochrane, A.L., Holland, W.W., Validation of screening procedures. Br. Med. Bull. 27:1 (1971), 3–8.
6. Coco, S., Truini, A., Vanni, I., et al. Next generation sequencing in non-small cell lung cancer: new avenues toward the personalized medicine. Curr. Drug Targets 16:1 (2015), 47–59.
7. Couraud, S., Vaca-Paniagua, F., Villar, S., et al. Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-of-concept study from BioCAST/IFCT-1002. Clin. Cancer Res. 20:17 (2014), 4613–4624.
8. Cree, I.A., Improved blood tests for cancer screening: general or specific?. BMC Cancer, 11, 2011, 499.
9. Cross, A.J., Moore, S.C., Boca, S., et al. A prospective study of serum metabolites and colorectal cancer risk. Cancer 120:19 (2014), 3049–3057.
10. Dowling, P., Clarke, C., Hennessy, K., et al. Analysis of acute-phase proteins, AHSG, C3, CLI, HP and SAA, reveals distinctive expression patterns associated with breast, colorectal and lung cancer. Int. J. Cancer 131:4 (2012), 911–923.
11. Etzioni, R., Urban, N., Ramsey, S., et al. The case for early detection. Nat. Rev. Cancer 3:4 (2003), 243–252.
12. Fortunato, O., Boeri, M., Verri, C., et al. Assessment of circulating microRNAs in plasma of lung cancer patients. Molecules 19:3 (2014), 3038–3054.
13. Gires, O., Stoecklein, N.H., Dynamic EpCAM expression on circulating and disseminating tumor cells: causes and consequences. Cell. Mol. Life Sci. 71:22 (2014), 4393–4402.
14. Gromov, P., Gromova, I., Bunkenborg, J., et al. Up-regulated proteins in the fluid bathing the tumour cell microenvironment as potential serological markers for early detection of cancer of the breast. Mol. Oncol. 4:1 (2010), 65–89.
15. Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144:5 (2011), 646–674.
16. Hasim, A., Aili, A., Maimaiti, A., Mamtimin, B., Abudula, A., Upur, H., Plasma-free amino acid profiling of cervical cancer and cervical intraepithelial neoplasia patients and its application for early detection. Mol. Biol. Rep. 40:10 (2013), 5853–5859.
17. Hauselmann, I., Borsig, L., Altered tumor-cell glycosylation promotes metastasis. Front Oncol., 4, 2014, 28.
18. Holdenrieder, S., Dharuman, Y., Standop, J., et al. Novel serum nucleosomics biomarkers for the detection of colorectal cancer. Anticancer Res. 34:5 (2014), 2357–2362.
19. Lo, Y.M., Circulating nucleic acids in plasma and serum: an overview. Ann. N. Y. Acad. Sci. 945 (2001), 1–7.
20. Lo, Y.M., Quantitative analysis of Epstein-Barr virus DNA in plasma and serum: applications to tumor detection and monitoring. Ann. N. Y. Acad. Sci. 945 (2001), 68–72.
21. Ludwig, N., Keller, A., Heisel, S., et al. Improving seroreactivity-based detection of glioma. Neoplasia 11:12 (2009), 1383–1389.
22. McPhail, S., Johnson, S., Greenberg, D., Peake, M., Rous, B., Stage at diagnosis and early mortality from cancer in England. Br. J. Cancer 112:Suppl. 1 (2015), S108–S115.
23. Middleton, C.H., Irving, W., Robertson, J.F., et al. Serum autoantibody measurement for the detection of hepatocellular carcinoma. PLoS One, 9(8), 2014, e103867.
24. Molina, R., Bosch, X., Auge, J.M., et al. Utility of serum tumor markers as an aid in the differential diagnosis of patients with clinical suspicion of cancer and in patients with cancer of unknown primary site. Tumour Biol. 33:2 (2012), 463–474.
25. Paterson, C.R., Robins, S.P., Horobin, J.M., Preece, P.E., Cuschieri, A., Pyridinium crosslinks as markers of bone resorption in patients with breast cancer. Br. J. Cancer 64:5 (1991), 884–886.
26. Rothe, F., Laes, J.F., Lambrechts, D., et al. Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer. Ann. Oncol. 25:10 (2014), 1959–1965.
27. Roy, R., Yang, J., Moses, M.A., Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 27:31 (2009), 5287–5297.
28. Schechter, G.B., Lopes, J.D., Two-site immunoassays for the measurement of serum laminin: correlation with breast cancer staging and presence of auto-antibodies. Braz. J. Med. Biol. Res. Rev. Bras. Pesqui. Med. Biol. Soc. Bras. de Biofisica 23:2 (1990), 141–149.
29. Wilson, J.M., Jungner, Y.G., Principles and practice of mass screening for disease. Bol. Of Sanit Panam. Pan Am. Sanit. Bur. 65:4 (1968), 281–393.
30. Wolf, A.M., Wender, R.C., Etzioni, R.B., et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J. Clin. 60:2 (2010), 70–98.
31. Wu, J., Xie, X., Liu, Y., et al. Identification and confirmation of differentially expressed fucosylated glycoproteins in the serum of ovarian cancer patients using a lectin array and LC-MS/MS. J. Proteome Res. 11:9 (2012), 4541–4552.